These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17001461)

  • 1. Treatment of neuroendocrine tumors with somatostatin analogs.
    Janson ET
    Pituitary; 2006; 9(3):249-56. PubMed ID: 17001461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of somatostatin analogues in the treatment of neuroendocrine tumors.
    Narayanan S; Kunz PL
    J Natl Compr Canc Netw; 2015 Jan; 13(1):109-17; quiz 117. PubMed ID: 25583773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
    Strosberg J; Kvols L
    World J Gastroenterol; 2010 Jun; 16(24):2963-70. PubMed ID: 20572298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The place of somatostatin analogs in the diagnosis and treatment of the neuoroendocrine glands tumors.
    Melen-Mucha G; Lawnicka H; Kierszniewska-Stepien D; Komorowski J; Stepien H
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):237-54. PubMed ID: 18221040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
    Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B
    Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook.
    Eriksson B; Oberg K
    Ann Oncol; 1999; 10 Suppl 2():S31-8. PubMed ID: 10399030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
    Narayanan S; Kunz PL
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.
    Veenstra MJ; de Herder WW; Feelders RA; Hofland LJ
    Expert Opin Ther Targets; 2013 Nov; 17(11):1329-43. PubMed ID: 23991721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
    Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
    Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When and How to Use Somatostatin Analogues.
    de Herder WW
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):549-555. PubMed ID: 30098715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
    Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin analogs for the treatment of neuroendocrine tumors.
    Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C; Caplin ME
    Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
    Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET; Oberg K
    Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
    Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Somatostatin Analogues in Oncology. European Neuroendocrine Tumor Network (ENET). February 24-27, 2000, Innsbruck, Austria. Proceedings.
    Digestion; 2000; 62 Suppl 1():1-108. PubMed ID: 11001649
    [No Abstract]   [Full Text] [Related]  

  • 19. [Medical treatment of digestive neuroendocrine tumours].
    Panzuto F; Nasoni S; Delle Fave G
    Minerva Endocrinol; 2001 Sep; 26(3):145-8. PubMed ID: 11753237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
    Hofsli E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.